Effectiveness of cold cap in the prevention of docetaxel-induced alopecia.
Docetaxel is a new taxoid antineoplastic agent with clinical efficacy especially in breast cancer. One of the most distressing side-effects induced by docetaxel is alopecia. We studied the prevention of alopecia by using a cold cap in 98 patients receiving 100 mg/m2 docetaxel by 1 h i.v. infusion every 3 weeks. One patient was lost to follow-up. 83 patients (86%) were evaluated as a success to the cold cap, as they presented WHO grade alopecia < or = 2 and no need to wear a wig. 14 patients (14%) had to wear a wig; among them; 7 patients withdrew before the evaluation at three cycles. The cold cap is a very effective technique with minimal side-effects for docetaxel-treated patients.
Lemenager
M
M
Centre Oscar Lambret, Lille, France.
Lecomte
S
S
Bonneterre
M E
ME
Bessa
E
E
Dauba
J
J
Bonneterre
J
J
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced / Q000517:prevention & control*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D017679:Cryotherapy; D000077143:Docetaxel; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives*; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel